MagicMed Raises $1.6M to Launch Psychedelic Drug Discovery Platform

MagicMed Industries Inc. raised roughly $1.6 million in an oversubscribed private placement to develop Psybrary™—a proprietary drug discovery platform for the psychedelics industry. Using its deep expertise in molecular derivatives, the company aims to develop a library of derivative variant molecules that partners can develop into therapeutics.

Let’s take a closer look at why the company’s unique business model has drawn so many investors and where to learn more as it moves closer to going public.

Unique Business Model

MagicMed Industries aims to develop a library of new derivative variant molecules based on natural psychedelic molecules, such as psilocybin. With deep expertise in the field, the company’s team will leverage proprietary trade secrets developed in-house from decades of research and development in the field of natural product biochemistry.

The company plans to seek out commercialization partners that will search, select and test derivatives from the Psybrary™ and use them as building blocks for their own product development based on the indications that they are targeting, such as anxiety, depression, addiction and post-traumatic stress disorder.

Once developed and approved, the company’s partners will sell the products into medical and consumer markets. The derivative nature of the molecules means that they can be patented (unlike natural molecules), creating both unique characteristics and a competitive barrier to entry. The company could also expand into nutraceuticals and other OTC markets.

The unique business model provides both high-margin revenue and diversification across partners and indications. By charging a royalty to license molecules, the company avoids the high cost of clinical trials and product development while retaining the blue-sky potential to generate large amounts of revenue if drugs reach a blockbuster stage.

Click here to learn more about becoming an investor in MagicMed Industries Inc.

Alternative to Cannabis

Many cannabis investors have been turning to psychedelics as an emerging frontier investment. While the cannabis industry has matured, psychedelics remain in the early stages of product development, which could open the door to potentially greater returns. Many psychedelics companies are going public, opening the door to retail investors.

In addition to earlier stage opportunities, many investors are also drawn to the therapeutic potential for psychedelics. Cannabis has become a largely recreational business with thin profit margins in many localities, whereas most people know someone that suffers from a mental illness that could benefit from psychedelic therapies.

These sentiments were one reason that MAPS was able to raise $30 million in donations to fund its research on MDMA for post-traumatic stress disorder and a key reason that MagicMed Industries was able to not only reach its goal of raising $1 million but oversubscribe the offering by another roughly $600,000 amid soaring interest.

MagicMed Industries offers investors a prudent approach to the market. Rather than focusing on a single clinical trial or a commoditized consumer product line, the company is building a platform (like Amazon or Google) that other companies can build off of to create value and earn a margin off the top of any sales in exchange for the service.

Click here to learn more about becoming an investor in MagicMed Industries Inc.

Looking Ahead

MagicMed Industries’ move to raise $1.6 million marks another step on its way to becoming a leading drug discovery platform and a publicly traded company. With plans to go public during the first half of next year, investors may want to take a closer look at the company and follow its developments over the coming months.

On Thursday, September 3, 2020, investors can tune into the Microdose Conference to learn more about MagicMed’s capital raise and what the funds will be put towards. Sign up now!

To learn more about MagicMed Industries, sign up to download the investor presentation and receive corporate updates.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.